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Background: 25(OH) vitamin D levels may be low in patients with moderately or severely active inflammatory
bowel diseases (IBD: Crohn’s disease and Idiopathic Ulcerative Colitis) but this is less clear in patients with mild or
inactive IBD. Furthermore there is limited information of any family influence on 25(OH) vitamin D levels in IBD. As
a possible risk factor we hypothesize that vitamin D levels may also be low in families of IBD patients.
Objectives: To evaluate 25[OH] vitamin D levels in patients with IBD in remission or with mild activity. A second
objective is to evaluate whether there are relationships within IBD family units of 25[OH] vitamin D and what are
the influences associated with these levels.
Methods: Participants underwent medical history, physical examination and a 114 item diet questionnaire. Serum
25[OH] vitamin D was measured, using a radioimmunoassay kit, (replete≥ 75, insufficient 50–74, deficient < 25–50,
or severely deficient < 25 nmol/L). Associations between 25[OH] vitamin D and twenty variables were evaluated
using univariate regression. Multivariable analysis was also applied and intrafamilial dynamics were assessed.
Results: 55 patients and 48 controls with their respective families participated (N206). 25[OH] vitamin D levels
between patients and controls were similar (71.2 ± 32.8 vs. 68.3 ±26.2 nmol/L). Vitamin D supplements significantly
increased intake but correlation with serum 25[OH] vitamin D was significant only during non sunny months
among patients. Within family units, patients’ families had mean replete levels (82.3 ± 34.2 nmol/L) and a modest
correlation emerged during sunny months between patients and family (r2 =0.209 p = 0.032). These relationships
were less robust and non significant in controls and their families.
Conclusions: In patients with mild or inactive IBD 25[OH] vitamin D levels are less than ideal but are similar to
controls. Taken together collectively, the results of this study suggest that patient family dynamics may be different
in IBD units from that in control family units. However contrary to the hypothesis, intra familial vitamin D dynamics
do not pose additional risks for development of IBD.
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The discovery of immunoregulatory and antineoplastic
functions of vitamin D was followed by research to evaluate
its possible pathogenic and therapeutic roles in mul-
tiple diseases [1-3]. Epidemiological and observational
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reproduction in any medium, provided the or(UVB, 280 – 315 nm) with diminished risks of many
diseases [4-9] including general mortality [7].
The inflammatory bowel diseases (IBD: Crohn’s Disease
[CD] and Idiopathic Ulcerative Colitis [UC]) in particular
have been noted to have distinct latitudinal distributions
[10-12]. While pathogenesis of IBD remains elusive, envir-
onmental factors, the host’s intestinal microbial flora and
genetic immune modification putatively interact. Multiple
predisposing genes, many overlapping between CD and UC
have been described [13-15]. However, sunshine and UVBtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have been associated with lower serum 25[OH] vitamin
D levels [16,17] but the association is stronger with CD
[2,18-23]. Although, not yet proven two trials have been
published using supplemental vitamin D for therapy of CD
[24]. One suggested a possible reduction in clinical relapse
[25]. Evaluation of 25[OH] vitamin D levels in patients with
moderate or severe IBD have shown low levels [16,17] but
mild or inactive IBD has been studied less frequently.
Vitamin D functions and levels have also been linked
with genetic determinants. Vitamin D receptors (VDR)
responsible for cell signaling in response to metabolites
of vitamin D, have been found within several cell sys-
tems. These have been suggested to play a role in IBD
[26-28]. In addition 25[OH] vitamin D levels also relate
to genetic polymorphisms controlling Vitamin D binding
proteins (VDBP) [29,30]. These studies raise questions
about possible genetic links determining serum 25[OH]
vitamin D levels within families. However, there have been
limited reports evaluating intrafamilial relationships of 25
[OH] vitamin D levels. An early study from Manitoba in
Canada found poor diet led to low 25(OH) vitamin D levels
in mothers and infants [31]. Similarly a study from Jordan
reported low 25(OH) vitamin D levels in both rachitic
infants and their mothers. In this case prolonged breast
feeding, poor diet and/or low sun exposure were blamed
for the observation [32]. These studies suggest also that
low family levels may be determined by environmental
issues and may pose a risk for development of diseases.
The aims of this cross-sectional study were to compare
serum 25[OH] vitamin D levels in a cohort of IBD patients
with mild or inactive disease to a cohort of healthy controls.
Furthermore we compared these levels with a first degree
family member and to make a second comparison be-
tween IBD families to healthy controls and their families.
Common clinical variables were looked at and evaluated
with respect to their association with levels of 25[OH]
vitamin D. We then evaluated the relationships of 25
[OH] vitamin D levels within both family units of IBD and
controls. We hypothesized that low levels of vitamin D re-
ported in IBD patients may be reflected in family members,
thus constituting an additional family risk for IBD.
Methods
Patients
This study was carried out at the Jewish General Hospital
from March 1, 2009 to April 30, 2011. Approval was ob-
tained from the ethics and review board of the hospital.
Patients were invited to participate and recruited from
the department’s IBD clinics as well as from gastroen-
terologists’ practices. Each patient was asked to invite a
first degree family member to be evaluated at the same
time as the patients. Family members were self chosen by
their availability for time to participate. Each participantgave informed signed consent. The diagnosis of Crohn’s
disease (CD) or ulcerative colitis (UC) was based on
accepted criteria from previous evaluations (history,
physical examination, radiology and/or histology) [33].
The recruited patients from clinics were stable (no change
in medications for at least 3 months) and had mild or
inactive disease). Each patient was assessed at entry
into the study and was assigned a clinical index score
based on well established criteria. In the case of CD,
activity was assessed by the Harvey Bradshaw index
[HBI] [34]. For UC the Simple Clinical Colitis Activity
Index [SCCAI] was used [35]. In each case both the
HBI and SCCAI, the score of ≤ 4 indicates remission.
Family members recruited were healthy or had stable
(same definition as for stable patients) chronic diseases
(hypertension, thyroid hormone replacement or hyper-
cholesterolemia). However diabetes (types 1 and 2),
known Celiac disease, other malabsorptive diseases or
renal disease were excluded.
A control population was recruited by advertising for
health care workers or other employees in the hospital,
word of mouth or on university bulletin boards. These
were recruited in groups following initial recruitment of
patients. The controls were profiled to resemble patients
with respect to age, sex, ethnicity and weight. First degree
family members of controls (also self chosen by availability
of time) were recruited with the same restriction as for
patients’ families. There was no attempt to profile family
members of controls with family members of patients.
Interventions
Clinical assessment
Participants presented usually as a family unit on the
day of the evaluation. All individuals underwent a brief
history, physical examination including Body Mass Index
(BMI: Kg/M2) measurement and a series of blood tests for
complete blood count, C-reactive protein, kidney function,
biochemistry including calcium albumin and iron studies
(ferritin and % saturation). In addition serum vitamin 25
(OH) D levels were measured.
Dietary assessment
After brief explanations, all participants completed a 114
item diet questionnaire This questionnaire was presented
as a 5-page food frequency questionnaire (FFQ) which
was developed and adapted from previously validated
questionnaires. The FFQ is a general survey and is not
dependent on specific time exposure to the foods. We
used a diet limited FFQ to measure daily dietary calcium
[87 items] [36], lactose [27 items] and vitamin D intakes
[37]. Open-ended questions were included to identify
potential contributors and nutrient interactions as dietary
supplements and medications. Total daily intake of vitamin
D and calcium included both within diet and supplements
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are derived from dairy foods (mostly fluid milk). Lactose is
a good surrogate for dairy foods as 12.5 g serving of lactose
approximates the content of a 250 ml volume of fluid milk.
Determination of portion sizes was done using 2-
dimension food models. A sample of any supplement
was requested from participants. A systematic revision
of each FFQ was performed by a dietician (SG and MM)
and participants were contacted for any clarifications.
Double-blinded data entry and analysis was performed
using an Excel spreadsheet calculator. Nutrient values
extracted from the Canadian Nutrient File 2007 [38] as
well as the United States Dietary Association were used
as references [39].
Vitamin D measurements
Serum 25[OH] vitamin D was measured using an
RIA kit as used in the hospital clinical chemistry unit
(Immunodiagnostic Systems Ltd. IDS 10 Didcot Way
Boldon Business Park, Boldon, Tyne and Wear NE35 9PD).
The specificity is 100% for both 25-Hydroxy Vitamin D3
and 24, 25 Hydroxyvitamin D3 and 75% for 25 Hydroxy
Vitamin D2.
The interassay precision at 58.7 nmol/L was SD −4.8 and
CV of 8.2%. Serum 25(OH) vitamin D levels were reported
in nmol/L and daily intake levels in International Units.
The North American 25(OH) vitamin D level guidelines
were used to classify patients into replete ≥ 75 nmol/L,
insufficient 50–74 nmol/L, deficient < 50 nmol/L or se-
verely deficient <25 nmol/L [20,40].
Twenty variables were evaluated to determine univariate
relationships to serum 25(OH) vitamin D levels. These
variables included age, sex, BMI, race, ethnicity, smoking
history, use of tanning salons (relevant in winter only), vac-
ation 1 month prior to blood tests (relevant in winter only),
total vitamin D intake, dietary and supplemental vita-
min D intake, dairy food intake total calcium intake,
dietary and supplemental calcium intake, disease ver-
sus no disease, corticosteroid intake, duration of dis-
ease, and in CD patients, whether colon or small bowel
were affected. Additional effect of UVB was evaluated
by assessing month of test and dividing time of test-
ing either into sunny (May – September) or less sunny
(October –April) months.
Statistical analysis
First, descriptive statistics (including means with standard
deviations and proportions) were used to describe
demographic characteristics, 25(OH) vitamin D serum
levels, vitamin D and calcium intakes among patients,
controls and their family groups Because these values
were skewed in groups, some statistical comparisons were
based on log 25(OH) vitamin D and were indicated as such.
We used unpaired tests (two-sample t-test, chi-square test,or Fisher’s exact test) to compare levels (i.e. serum 25(OH)
vitamin D levels, vitamin D and calcium intakes) between
patients and controls, and paired tests (paired t-test or
McNemar’s test for correlated proportions) between
patients and their families, and between controls and
their families, because we assumed that measured levels
within family units were not independent. We then calcu-
lated correlations to examine the relationships accounting
for seasons between vitamin D intake and 25(OH) vitamin
D serum levels between patients and their family group
and between controls and their family group, separately
by different seasons. We used linear regression with log
serum vitamin 25(OH) D as the outcome in univariate
and multivariable analysis in order to identify variables that
were significantly associated with serum 25(OH) vitamin D
levels. Regression analyses were conducted only among the
combined sample of patients and controls, because these
individuals were considered independent of one another.
Finally, we examined and graphed the correlations of log
serum vitamin 25(OH) D between patients and family, and
between controls and family, separately by seasons.
All tests were two-tailed and statistical significance
was accepted at p ≤ 0.05. Analyses were conducted using




A total of 244 people were approached over the 25 month
period. All participants lived in Montreal and usually within
the same geographic area. Of these 38 were excluded from
analysis because they did not meet criteria as described
above. Two hundred and six participants remained to be
analyzed. Within another 13 participants (6%) 25(OH) vita-
min D levels were inadvertently missing and are outlined in
tables, leaving 193 for 25 (OH) vitamin D analyses. When
possible participants with missing levels were still included
for assessment of dietary intakes.
After excluding individuals from the study there
remained, 55 patients (21 UC and 34 CD) along with
55 first degree family members and 48 controls together
with 48 of their family members. The distribution of fam-
ily members were as follows: IBD relative family members,
mothers 42.6%,daughters 18.5%, sisters 16.7%, and fathers,
brothers, sons each 7.3%. Control family members were
daughters 29%, sons 23%, mothers 17%, sisters 16.7%,
brothers 8%, fathers 6.3%. Demographics of IBD patients
are described in Table 1. The majority were female with no
significant difference in age between CD and UC patients.
The majority in each IBD group were in remission with a
mean HBI score of 2.6 ± 1.9 for CD and SCCAI of 2 ± 1.3
for UC. In the CD group however, 7 patients had a mean
HBI score of 5.7 indicating mild activity (this represents
20.6% of the CD group and 12.7% of the entire group).
Table 1 Demographics Counts (%) are reported unless otherwise noted











Age, mean ± SD 39.9 ± 12.3 yr 44.2 ± 13.7 yr 46.5 ± 21.6 yr 39.6 ± 13.8 yr 30.5 ± 18.7 yr
Sex: female 21 (61.8%) 13 (61.9%) 42 (76.4%) 38 (79.2%) 30 (62.5%)
BMI, mean ± SD 24.2 ± 4.1 kg/m2 25.4 ± 3.2 kg/m2 24.6 ± 4.6 kg/m2 25.7 ± 7.9 kg/m2 24.9 ± 6.5 kg/m2
Ethnicity: Caucasian* 32 (94.1%) 20 (95.2%) 51 (92.7%) 38 (79.2%) 38 (79.2%)
Jewish 15 (44.1%) 13 (61.9%) 29 (52.7%) 20 (41.6%) 20 (41.6%)
Seasons: Sunny: May - Sept 15 (44.1%) 10 (47.6%) 28 (50.9%) 21 (43.8%) 22 (45.8%)
Less Sunny:
Oct. - Apr
19 (55.9%) 11 (52.3%) 27 (49.1%) 27 (56.3%) 26 (54.2%)
Smoking^ 3 (8.8%) 3 (14.3) 5 (9.1%)^ 6 (12.5)% 2 (4.2)%
Regular tanning^ 0 1 (4.8%) 0 1 (2.1)% 1 (2.1)%
Vacation 1 month pretest^ 4 (11.8%) 0 3 (5.5)% 4 (8.3%) 1 (2.1)%
Activity score**, mean ± SD 2.6 ± 1.9
(20.6% mild active)
2 ± 1.3 (0% active)
Disease Duration, mean ± SD 85.6 ± 140.2 month 39.7 ± 53.5 month
Site of disease Colon 13 (38.2%) Pan Colitis: 16 (76.2%)
Ileo-colon 12 (35.3%) Left limit: 4 (19%)
Small bowel 9 (26.6%) Unclear: 1 (5%)
Medical: 5ASA 6 (17.7%) 17 (81%) 0 1 diagnosed with leukemia
Corticosteroids 4 (11.8%) 4 (19%)
Immunomodulators 5 (14.7%) N1 (4.8%)
Biologics 3 (8.8%) 3 (14.3%)





* Chi-square comparison of Caucasian in Patient vs. Controls yields p = 0.019.
^ Missing information on participants ranged from 25-50%.
** Score for Crohn’s based on Harvey Bradshaw Index [34] Inactive ≤ 4.
Score for Ulcerative Colitis based on Simple Clinical Colitis activity Index [35]. Inactive < 4.
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show a modest inverse correlation (r2 = 0.057, r =− 0.24)
[data not shown]. These 7 also had elevations of CRP. None
of the UC patients demonstrated activity by scores, although
4 had elevated CRP. CRP levels did not correlate well in
10 patients with available serum 25(OH) vitamin D levels
[n = 10 patients], (r2 = 0.001, r = 0.029) [data not shown].
More than half of the patients were Jewish and only
6% were non Caucasians. The CD patients had their dis-
ease twice as long as the UC patients. The distribution of
CD was mainly colon or colon and terminal ileum. None
had gastric or duodenal disease based on current history
and previous endoscopy or radiological assessment. Of the
UC patients 75% had pancolitis and the others had left
sided disease only. As expected 5-Amino Salicylic Acid
(5ASA) use was common in UC but less than 20% in CD.
Immunomodulators and biologics were used in a minority
of patients. In the CD group 14 patients underwent at leastone previous operation. One patient with UC had a re-
mote colectomy. Table 1 outlines the demographics of
families of IBD patients, controls and their families.
Similar to the patient’s group the majority of family
members were female and there was no significant age
difference from patients. Family members of patients
were a decade older than family members of controls.
Two controls and 2 family members of controls had CRP
elevations. Non Caucasians were unevenly distributed in
the groups (patients 3/55 [5.5%] and controls 10/48 [20.8%]
respectively (Fisher’s p = 0.034).
Dynamics of vitamin D in groups
Serum 25 (OH) vitamin D levels across 4 study groups
The results of measured 25(OH) vitamin D levels and
their distributional rank criteria as described in the
method section are shown in Table 2. There was no sig-
nificant difference in levels or distribution of vitamin D
Table 2 Serum 25[OH] vitamin D by Groups
Group* Serum Vit 25(OH) D Replete: ≥ 75 Insufficient: 50-74 Deficient: < 50
mean ± SD n (%) n (%) n (%)
IBD Patients 71.2 ± 32.8** 21 (38.2%) 12 (21.8%) 17 (30.9%)
15(71.4%) 3 (25%) 8 (47.1%)
Crohn’s Disease 71.1 ± 31.1 14 (41.2%) 7 (20.6%) 10 (29.4%)
9 (64.3%) 2 (28.6%) 5 (50%)
Ulcerative Colitis 71.4 ± 36.3 7 (33.3%) 5 (23.8%) 7 (33.3%)
6 (85.7%) 1 (20%) 3 (42.9%)
Patients’ Family 82.3 ± 34.2 27 (49.1%) 18 (32.7%) 7 (12.7%)
13 (48.2%) 5 (27.8%) 1 (14.3%)
Healthy Control 68.3 ± 26.2 15 (31.3%) 19 (39.6%) 11 (22.9%)
7 (46.7%) 11 (57.9%) 4 (36.4%)
Controls’ Family 69.9 ± 27.6 19 (39.6%) 16 (33.3%) 11 (22.9%)
8 (88.9%) 5 (31.3%) 1 (9.1%)
Levels and categories of serum 25[OH] vitamin D in nmol/L overall and by patient, control and their respective families are shown. The lower values represent the
number of participants in each category who consumed supplemental vitamin D and the percentage of the category in each group. Based on (n = 193) available
serum levels.
* Because of some missing data on serum 25[OH] vitamin D levels, percentages do not sum to 100%. Missing data were as follows:
5 from IBD.
3 from Family IBD.
3 from Control.
2 from Family Control.
** patient vs. family: p = 0.0332 (paired t test) or p = 0.0164 (for log values).
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IBD group and controls. One patient with UC had a level
of 25(OH) vitamin D < 25 nmol/L (severe deficiency). The
mean serum 25(OH) vitamin D levels in the IBD family
group was significantly higher than patients’, using paired
t test for both actual and log values.
Association of vitamin D intake, calcium intake, and season
with serum 25(OH) vitamin D levels
Description of daily vitamin D (total = dietary + sup-
plements) and calcium (total = dietary + supplements)
intake in the four groups is shown in Table 3. The
number of participants who consumed vitamin D sup-
plements in each study group is also reported. Controls
consumed more daily vitamin D, without statistically
significant differences in intake between patients and
controls. However, supplemental vitamin D daily intake
significantly increased intake, to a range of 1100 – 1350
(Table 3). Although higher than the RDA, these do not
approach the tolerable upper limit (UL) for vitamin D of
4000 IU for children > 9 yrs. and adults. Patients and
controls had similar frequency of supplementary intake
of vitamin D: patients: 53%, IBD family: 36%, healthy
controls: 48%, controls family: 31%.
Table 4 contains average serum 25[OH] vitamin D levels
across categories of vitamin D intake with and without
supplements, and across seasons, for each study group.
Frequency toward replete levels increased but statistical
significance was achieved only in patients dependingon analysis (mean ± SD, p = 0.03 or mean log vitamin D,
p = 0.059).
Intake of calcium appeared to affect 25[OH] vitamin
D levels but this was evident mainly in controls (data
not shown). Calcium supplements were used by 58% and
46% of patients and controls respectively (NS). Similarly
controls consumed more calcium than IBD patients, but
the difference was not statistically significant. Controls
did consume about twice as much dairy foods as patients
(lactose: Controls, 21.9 g/d, Patients, 11.7 g/d, p = 0.01).
Regarding seasons, serum 25[OH] vitamin D levels
in patients only were significantly increased in sunny
months May – September compared to less sunny
months October – April (Table 4). Among patients and
controls combined (N 95) the mean 25(OH) vitamin D
level during sunny months.
(N42, May – September) was 76.1 ±30.1 nmol/L
while during less sunny months (N53, October- April)
the level was 64.8 ±28.7 nmol/L (p = 0.046, for log 25
(OH) vitamin D).
Similarly taking a sunny vacation one month prior to
testing or using tanning salons resulted in higher levels
but there were too few participants for meaningful
statistical analysis.
Correlations between vitamin D intake and serum 25
[OH] vitamin D levels are shown in Figure 1a and 1b,
separately by seasons and for each study group. It is noted
that the association of vitamin D intake with serum levels
was more evident during less sunny months and was more
Table 3 Intake of total, dietary or supplemental vitamin D and calcium by groups
IBD Patients Patients’
family N = 55
Controls Controls’
family N = 48N =55 N = 48
Dietary Vit D intakes in each group, n 54 54 46 48
Mean ± SD IU 371 ± 333 527 ± 803 600 ± 848 666 ± 592
Median 286 260 394 416
Total Vit D Intakes in each group, n 54 54 46 48
Mean ± SD 784.4 ± 720 761.3 ± 881.6 917 ± 1028 867 ± 801
Median 599.5 523 590.2 612.
Total Vit D intakes in Subgroups with Supplemental Vit D, n 29 20 23 15
Mean ± SD 1110 ± 780* 1116.2 ± 809.7** 1279 ± 857** 1344.9 ± 994.2**
Median 932.4 932.8 1020.8 1191.1
Total Vit D intakes in Subgroups without Supplemental Vit D, n 23 34 23 32
Mean ± SD 404.2 ± 409.2 552.5 ± 865.8 554.3 ± 1074.4 648.4 ± 605.3
Median 332.8 291.7 290.4 377.4
Total Calcium Intakes in each group, n 54 54 46 48
Mean ± SD 1537.2 ± 755 1687.4 ± 1071.5 1778.7 ± 1127.2 1931.4 ± 1325.6
Median 1479 1404.7 1552.1 1679.5
Vitamin D intake is listed in International Units (conversion to μg is IU/40). Total daily calcium is listed as g/day. Vitamin D intakes were skewed and therefore
both mean ± standard deviation and median values are listed. N values for each group represents original number in the groups and n values actual
numbers analyzed.
Comparisons of means of groups with and without vitamin D supplements were significant; * p < 0.01, ** p < 0.05.
Grunbaum et al. Nutrition Journal 2013, 12:145 Page 6 of 11
http://www.nutritionj.com/content/12/1/145robust in patients (r2 = 0.315, r = 0.56, p = 0.003) than
in controls (r2 = 0.13, r = 0.36, p = 0.07). There was no
discernable effect of vitamin D intake by seasons in either
family group.
Univariate and multivariable analyses for serum 25(OH)
vitamin D in patients and controls combined
We analyzed 20 individual variables as described in the
methods section for univariate association with log serum
25(OH) vitamin D levels. Since there were no significantTable 4 Serum 25[OH] vitamin D according to intakes of vitam
Item IBD Patients
N = 55
25(OH)D levels in Supplement users, n 26
Mean ± SD 79.8 ± 36.5*
25(OH)D levels in non Supplement users, n 21
Mean ± SD 59.4 ± 25.0
Seasons:
May-Sept, n 23
Mean ± SD 81.6 ± 32.5 **
Oct-April, n 27
Mean ± SD 62.4 ± 31.0
The effects of vitamin D intake on 25[OH] vitamin D with or without supplement or
levels are reported as nmol/L. May –Sept are sunny months, October –April are non
groups and n values actual numbers analyzed.
* The comparison of means ± SD was significant (p = 0.03 compared with patients n
the result became nonsignifcant (p = 0.059).
** p = 0.039 compared with patients evaluated in October to April.differences in 25(OH) vitamin D levels between patients
and controls, these groups were combined for analyses.
Five variables were statistically significant: Jewish eth-
nicity, vacation one month prior to study testing, total
calcium intake, dietary (but not supplemental) calcium,
and seasonal measurement of levels. Five other vari-
ables reached marginal significance (p < 0.1). These
were total vitamin D intake, Caucasian race, BMI, diet-
ary (but not supplemental) vitamin D, and use of corti-
costeroids by patients.in D
Patients’
Family N = 55
Controls Controls’
Family N = 48N = 48
19 22 14
86.7 ± 24.1 70.2 ± 26.5 74.6 ± 15.9
32 22 31
79.9 ± 39.6 67.9 ± 26.1 68.2 ± 31.8
27 19 21
83.7 ± 32.1 69.5 ± 26.3 73.3 ± 30.9
25 26 25
80.8 ± 36.9 67.4 ± 26.6 67.1 ± 24.7
seasons of testing are shown for four groups. All serum 25[OH] vitamin D
sunny months. N values for each group represents original number in the
ot taking vitamin D supplements). However comparing log 25[OH] vitamin D
Figure 1 25[OH] vitamin D levels and the effect of intake in groups by seasons. a. Winter: Patients (N 26) (r2 = 0.315, r = 0.561, p = 0.003),
Families of patients (N25) (r2 < 0.001, r = 0.003, p = 0.990), Controls (N26) (r2 = 0.129, r = 0.359, p = 0.072) and Families of controls (N25) (r2 < 0.001,
r = 0.010, p = 0.961). b. Summer: Patients (N = 23): (r2 = 0.036, r = 0.191, p = 0.384), Families of patients (N26): (r2 = 0.024, r = −0.156, p = 0.448),
Controls (N18): (r2 = 0.018, r = −0.134, p = 0.597) and Families of controls (N21): (r2 = 0.092, r = 0.303, p = 0.182).
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than non Caucasians in both patients and controls
[Caucasian patients vs. non-Caucasian patients: 71.7 ± 33.6
vs. 64 ± 18 nmol/L respectively] [Caucasian controls vs.
non-Caucasian controls: 72.3 ± 22.8 vs. 54.5 ± 33.3 nmol/L
respectively]. In IBD and family groups only 3 non
Caucasians were included contributing little to mean
values of serum vitamin D. In the control group, 10
participants and 9 participants in their family group were
non Caucasians. Comparison of mean levels of 25[OH]
vitamin D for Caucasians versus non Caucasians was of
borderline significance in the controls (p = 0.0575) but was
more substantial in the control family (p = 0.003). Exclusionof all non Caucasians did raise the mean 25[OH] vitamin D
level to 75.6 ng/L). Comparison of means in Caucasian
patients with Caucasian controls after removal of non
Caucasians still showed no significant differences [71.7 ±
33.6 vs. 72.3 ± 22.8 (SD) nmol/L respectively NS].
In multivariable analysis seasonal testing, Jewish ethnicity,
intake of dietary calcium and intake of total vitamin D
remained in the model (n = 91).
Dynamics of Vitamin D within family units
Overall there was a modest non significant correlation
in log 25[OH] vitamin D levels within families (patients
and family r2 = 0.06, r = 0.24; p = 0.1 control and family
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separated by sunny or less sunny season of testing, the
levels of log values between patients and their families
became statistically significant (r2 = 0.209, r = 0.46, p = 0.032
in sunny months vs r2 = 0.0672, r = 0.26, p = 0.244 less sunny
months) (Figure 2a and 2c respectively). This altered
relationship was weaker between controls and their
families (r2 = 0.197, r = 0.44, p =0.065 more sunny months,
r2 = 0.007, r = 0.08, p = 0.695 less sunny months) (Figure 2b
and 2d).
Among the four groups, IBD family members had
the highest mean replete 25[OH] vitamin D levels
(82.3 ± 34.2 nmol/L) and highest frequency in this category
(49.1%, Table 2).
Comparison of the distribution of deficiency categories
was not significantly different between patient and
controls (chi-square p = 0.164), but was significantly
different between IBD patients and their family members
(McNemar’s p = 0.0102), indicating a more deficient state
in the patients.
Discussion
The main outcomes of this study are as follows. Firstly,
approximately 2/3 of individuals within the group of IBD
patients with mild or inactive disease have insufficient or
deficient 25[OH] vitamin D levels. However this is similar
to that found in healthy controls. We confirm seasonal
variation in 25[OH] vitamin D levels. Measurement ofFigure 2 Relationships of serum 25[OH] vitamin D levels within famili
serum VitD-25 of Patients vs. Families of patients in Summer (N22) (r2 = 0.20
c Controls vs. Families of controls in summer (N18) (r2 = 0.1969, r = 0.444, pserum 25[OH] vitamin D during sunny months signifi-
cantly affected patients levels. Overall consumption of
vitamin D supplements increased patient’s serum levels
(marginal statistical significance). Families of patients or
controls and their families appeared to be less affected
by these variables. The IBD families as a group, show
higher mean 25(OH) vitamin D level and more often
achieve replete status than patients. A modest but sig-
nificant relationship with patients’ levels becomes evi-
dent during sunny months.
Our definitions of the distributions for 25[OH] vitamin
D have an influence over the proportion of replete and
insufficient number in groups. The controversy over
acceptable levels of 25[OH] vitamin D continue and
are accentuated by the recent decision of the Institute
of Medicine (IOM) to endorse the 50 nmol/L as optimal
value for skeletal health [41]. If we accept the IOM def-
inition, 2/3 of patients and 3/4 of controls remain re-
plete. However, there is controversy whether levels of 25
[OH] vitamin D acceptable for skeletal health are also
applicable to autoimmune or other diseases and the
IOM decision was criticized [42]. Our hospital accepts
25[OH] vitamin D distributions at the higher levels as
defined herein. In this way about 60% of IBD patients
and 2/3 of controls remain insufficient. Other studies,
including mostly active cases have reported lower levels in
IBD [16,17,20-22], but others do report results similar to
our study [43,44]. In the current study, although only aes by seasons. a. Correlations, slopes and p-values for plots of log
98, r = 0.458, p = 0.032): b winter (N22) (r2 = 0.0672, r = 0.259, p = 0.24),
= 0.065), d in winter (N25) (r2 = 0.0068, r = 0.082, p = 0.6955).
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there was a weak inverse correlation with serum 25(OH)
vitamin D levels, suggesting that perhaps active disease is
the cause (or effect of) lower serum 25(OH) vitamin D in
such cases.
The impact of seasons and vitamin D intake
Evaluating the most relevant variables affecting serum 25
[OH] vitamin D levels, MVA ranked sunshine as the most
influential on serum levels. The effect of seasons on serum
25[OH] vitamin D has been previously described [22]. Sea-
sonal variation altered serum levels and the effect of vitamin
D intake on levels. The effects were more evident in patients
as sunshine compensated for intake in sunny months while
vitamin D intake affected 25[OH] vitamin D levels in non
sunny months. Still these effects did not as a whole com-
pensate enough to achieve uniform replete levels.
In the current study patients who consumed vitamin
D supplements had higher levels than those who relied
solely on diet, but levels still did not reach desired values.
About half the patients and controls consumed supple-
ments but almost 60% did not achieve replete levels. Never-
theless the intake of supplements was disappointing. Only
in the patient’s group was there an apparent important in-
crease in levels seconday in vitamin D supplemental intake
but did not reach conventional statistical significance. The
explanation for the effect on patients is not clear, especially
in the light of a recent finding that at least CD patients may
have a 35% less efficiency in absorption of vitamin D [45].
Therefore, larger quantities of vitamin D intake may
be needed in general and in winter in particular. At
least 1200 IU/d (15 μg) is required for replete levels [25].
However, Aloia suggested that 3200 IU/d should be used
for at least 2 months and a simulated model found that
4600 IU/d consistently achieved the 75 nmol/L mark [40].
The MVA also ranked Jewish ethnicity and dietary
calcium as important determinants of serum vitamin D
levels in this study. As explained in the results Jewish
ethnicity frequency was similar in both patients and
control groups. Their serum 25[OH] vitamin D levels
were not significantly different from non Jewish groups
but was more evident in the control group.
Dietary calcium was significantly related to serum
vitamin D levels but a relationship was only observed
in controls. The reason for this is not clear. It is pos-
sible that this variable reflected the increased dairy
food consumption in controls with increased vitamin
D added to such foods. Calcium intake can increase 25
[OH] vitamin D levels, when the source of both is from
milk but not other sources [46].
The impact of intrafamilial dynamics
Contrary to our expectations IBD family members as a
group had the highest rather than lowest mean 25[OH]vitamin D levels. The levels in patient’s families were signifi-
cantly higher than those in patients. The difference between
them was significantly greater than the difference noted be-
tween controls and their families. Furthermore a modest
but significant correlation in the IBD family unit emerged
during sunny months which was less evident in the control
family unit.
The reason(s) for these findings is (are) not clear. The
possibilities include chance, because of relatively few partic-
ipants in each group. Our control group may not have been
as healthy as expected. 25(OH) vitamin D results of current
controls were however, similar to those reported by others
[43,44] and were similar to another healthy control group
reported from Montreal [47].
The inclusion of more non Caucasians in the control
groups may have limited the 25[OH] vitamin D levels in
the controls and their families. Non Caucasians may have
lower 25[OH] vitamin D levels [48] However the numerical
advantage of the IBD families was only modestly dimin-
ished by removal of the non Caucasians from controls. Fur-
thermore the consistent relationships, observed in patients
and the family unit rather than controls and their family
unit, reduces somewhat the role of chance or the inclusion
of excessive non Caucasians in the latter family unit.
Still, it is possible that intra family dynamics are differ-
ent between Caucasians and non Caucasians and this
may have influenced intra family results.
In view of intra IBD family unit observations proposal of
a genetic link unique to IBD patients and their families is
tempting. However, failure to recruit both parents and
inclusion of random single family members instead, di-
lutes ability to detect firm connections. Other undetected
variables may also have contributed.
Limitations of study
Limitations in this study need to be considered. Firstly
there are a paucity of participants and lack of homogeneity
of the IBD group. The use of the combination of IBD
patients rests on the similar 25[OH] vitamin D levels
found in both groups. A second limitation is the use of
clinical indexes to define clinical status of patients. Al-
though, well recognized as markers of activity the HBI or
SCCI do not preclude false judgment of remission or activ-
ity. The presence of symptoms may indicate irritable bowel
related symptoms or those secondary to previous surgery
(eg. diarrhea). In conjunction with this notion is that we
evaluated patient’s status on a single blood test measure-
ment, which does not allow any longitudinal assessment of
clinical course. A third limitation is the absence of data in
different categories. Most of these were inadvertent but
data that were not available were not used to derive effects
on serum vitamin D. In other situations however available
data were used to answer questions pertaining to an out-
come. For example intake of vitamin D was used to derive
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serum levels if those values were unavailable. Another limi-
tation was in the way the data were analyzed (combination
of patients and controls for effects of variables) may
have precluded demonstration of disease effect on 25[OH]
vitamin D levels. With the exception of a weak impact of
corticosteroids, none of the previously shown effects of
IBD on 25[OH] vitamin D levels were found [20,49,50].
However, the reason for lack of disease effect, may also
relate to the clinical stability of our patients which mostly
included inactive or mildly active disease. This suggests
that disease activity is more likely an important determin-
ant of serum 25[OH] vitamin D.
Conclusions
We report on 25[OH] vitamin D levels in a practical clinical
setting for stable IBD patients predominantly in remission.
Seasonal effects and the intake of vitamin D supplements
appeared to be more evident in the IBD family unit largely
driven by patients reactions.
Taken together this study suggests different vitamin D
dynamics in patient’s family units than in control’s family
units. The explanation for these observations is not evident
from this study. However, it does suggest that further
evaluation is needed to determine optimal vitamin D
intake to uniformly achieve replete levels in IBD. Further-
more we demonstrate that IBD family vitamin D dynamics
do not increase risk for these diseases. Further work would
be needed to determine whether these dynamic differences
can be reproduced.
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